Phase 3 EMERALD Trial: Recent Post Hoc Exploratory Analysis of Progression-Free Survival (PFS) Across Subgroups : Episode 4

Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease

November 25, 2024

By Rahul Gosain, MD
Rohit Gosain, MD

Opinion

Video

Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 analysis, which identified the duration of prior CDK4/6 inhibitor (CDK4/6i) therapy as a potential surrogate marker for endocrine sensitivity, and discusses how these findings could help guide the selection of optimal candidates for elacestrant treatment.

EP: 1.Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC

EP: 2.Incidence of ESR1 mutations and best practices for testing

EP: 3.Co-occurrence of ESR1m with other alterations

Now Viewing

EP: 4.Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease

At SABCS 2022, an interesting analysis looked at the duration of prior CDK4/6i as a surrogate marker for endocrine sensitivity. Could you elaborate on those data and their potential to inform the selection of optimal candidates for elacestrant?